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Abstract
Atypical Toxoplasma gondii strains, unrelated to archetypal clonal lineages (I, II, III), have been reported more frequently over the last
decade in areas other than Europe and North America. A newly described form of toxoplasmosis, ‘Amazonian toxoplasmosis’ (AT), has
been reported since 2002 in French Guiana. It is characterized by severe cases and atypical strains linked to a neotropical forest-based
cycle. We report on the cases of AT that required intensive care management. We performed a prospective observational study on hos-
pitalized adults in the Intensive Care Unit (ICU) from 2002 to 2008. Clinical and laboratory data, microbiological findings and outcomes
were recorded. Data, including the ICU simplified acute physiology score and the pneumonia severity index, were calculated. Epidemio-
logical risk factors for AT were assessed through questionnaires. Eleven non-immunodeficient patients were admitted to the ICU in
Cayenne for life-threatening pneumonia associated with disseminated toxoplasmosis. Mechanical ventilation was necessary in seven
patients, four of whom required immediate orotracheal intubation. Cardiac and ophthalmological abnormalities were found in five and
four patients, respectively. One patient died from multiple organ failure. The genetic characterization of Toxoplasma DNA using six micro-
satellite markers revealed unique and atypical genotypes in eight patients. All patients presented epidemiological risk factors for AT. In
French Guiana, significant T. gondii-related infectious syndrome associated with the lungs, a high level of LDH activity and the reported
risk factors for AT was strongly suggestive of disseminated toxoplasmosis with a possible trend toward life-threatening pneumonia.
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Introduction
Some reports from South America suggest a higher human
pathogenicity [1–4] of newly discovered genotypes of T. gon-
dii. Particular epidemiological and bioclinical features have
been reported during individual infections or community
outbreaks in immunocompetent adults and children in
French Guiana and Suriname since 1998 [5–7]. All the
strains isolated had atypical genotypes and appeared to be
linked to a neotropical forest-based cycle involving wild
felids and their prey [8–10]. These case reports helped to
define a new form of toxoplasmosis, ‘‘Amazonian toxoplas-
mosis’’ (AT). Through 11 case reports, we describe the
most severe form of AT, a disseminated toxoplasmosis with
life-threatening pneumonia, occurring in French Guianese
adults from 2002 to 2008. Each patient required intensive
care management, as they displayed at least one form of
organ failure.
ª2011 The Authors
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Materials and Methods
Study site
This study was performed in the ten-bed medical–surgical
Intensive Care Unit (ICU) of Cayenne Hospital in French
Guiana, which is a French overseas department of 220 000
inhabitants neighbouring Brazil and Suriname in the Amazo-
nian region.
Patient selection
A prospective analysis was carried out on all consecutive
adult non-immunodeficient patients that were admitted to
the Cayenne Hospital ICU and diagnosed with acute toxo-
plasmosis from 2002 to 2008.
Data
Data were collected from patient medical records: (i) general
demographic data; (ii) laboratory analysis, microbiology, radi-
ology variables and additional explorations such as ophthal-
mological examinations (for nine patients) and/or cardiac
ultrasonography (for ten patients) depending on the signs;
and (iii) the reasons for admission to the ICU, the hospital
and ICU length of stay (LOS), the ICU scoring system at
admission, and the life-support treatment and drugs pre-
scribed in the ICU. Epidemiological risk factors for AT (bio-
tope of residence, meat-borne risk factors and contact with
forestry elements) were obtained from individual patients
through interviews when possible or from the patient’s fam-
ily. All patients and/or relatives gave informed consents.
Toxoplasmosis diagnosis
Acute toxoplasmosis was defined as serological evidence of
recent Toxoplasma infection corresponding to the presence of
Toxoplasma-specific IgM with seroconversion or a significant
increase in IgG anti-Toxoplasma antibody titres. Patient serum
samples were analysed using an enzyme immunoassay (EIA) kit
to detect Toxoplasma-specific IgG and IgM (Abbott Diagnos-
tics, Abbott Park, IL, USA). Patient specimens (12 blood sam-
ples, five pulmonary fluids, one pleural fluid and one muscular
biopsy) were sent for DNA analysis to the National Reference
Center for Toxoplasmosis (Limoges, France) 3–14 days after
collection. A Qiagen DNA Mini Kit (Hilden, Germany) was
used to extract DNA from these samples and a PCR-based
assay was performed to detect the T. gondii B1 gene [11]. Toxo-
plasma DNA for genotyping was extracted directly from
bronchoalveolar lavage (BAL) or bronchial aspiration (BA)
samples (cases no. 4, 5 and 10) and indirectly from infected
mouse ascitic fluid after the inoculation of blood samples
(cases no. 1, 2, 6, 8 and 11). DNA was genotyped by compar-
ing length polymorphisms in six microsatellite markers (TUB2,
W35, TgM-A, B18, B17 and M33), as described elsewhere [12].
Medical and ICU scoring systems
We calculated the ICU Simplified Acute Physiology Score
(SAPS II) during the first 24 h of admission [13]. This point
scale, ranging from zero to 163, corresponds to a predicted
mortality between 0% and 100%. The pneumonia severity
index (PSI) is used to classify the severity of a patient’s com-
munity-acquired pneumonia (CAP) before ICU admission as
described by Fine et al. [14], and make appropriate site-of-
care decisions. Patients can be stratified into five risk catego-
ries (risk classes I-V) that are used to predict 30-day survival.
Retroviral investigation
All patients were tested for HIV serological status using two
HIV tests by EIA (Abbott, Biorad, Hercules, CA, USA or Bio-
me´rieux, Marcy l’Etoile, France). The Murex HTLV-1/2 EIA
test (Abbott) was used to screen for human T lymphotropic
virus status.
Microbiology differential diagnosis
Additional tests, including serological tests, direct examina-
tion, media culture or PCR-based tests were performed on
patients’ samples (blood, cerebrospinal fluid, BAL, sputum
and gastric aspirations) for differential diagnosis: malaria,
tuberculosis, Q fever, leptospirosis, infection with Chlamydia
sp, Mycoplasma pneumoniae, Legionella pneumophila, Rickettsia
sp, Pneumocystis sp, Histoplasma capsulatum or other exotic
fungi, Epstein-Bar virus, cytomegalovirus, respiratory syncytial
virus and arbovirus. Bronchoscopic samples were obtained
based on clinical features and CAP management guidelines.
Cytology was performed on BAL from seven patients.
Results
From January 2002 to December 2008, 11 patients were
admitted to the Cayenne Hospital ICU for life-threatening
pneumonia with disseminated toxoplasmosis. Two of the 11
patients had been previously described by Carme et al. [6].
Epidemiological description of the study population
The median age was 28 years (range, 18–41) and there was
a predominance of men (nine patients) and Maroon people
(seven patients) (Table 1 and Fig. 1). Eight patients were per-
manently living in the forest, but all presented risk factors
for AT in the 2 weeks before the onset of symptoms. Die-
tary risk factors were reported for eight patients, and the
animal eaten was clearly identified in four patients. Meat
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consumption was regular in cases 1, 3 and 6, making it diffi-
cult to reliably identify which type of meat was responsible
for the infection. Environmental risk factors for patient 2
were clearly identified, as he was a vegetarian and a healer,
and thus was used to handling plants from the forest.
Medical characteristics of patients
None of the other patients presented relevant medical
history, except one patient who had homozygous sickle cell
disease (case 1) (Tables 2 and 3). The main clinical presenta-
tion consisted of a sudden, significant non-specific infectious
syndrome with (i) a history of high (median value of 40C),
prolonged (lasting more than 15 days) and continuous fever,
(ii) a slow major general decrease in health with progressive
weight loss, anorexia and weakness that started with the
onset of symptoms, and (iii) lung involvement. Hepatomegaly,
splenomegaly or lymph node enlargement was found, and
cardiac or ophthalmological abnormalities were described in
five and four patients, respectively. One patient had anasarca
with hemodynamic instability. The patient’s initial symptoms
quickly developed into a severe sepsis-like infection, mainly
associated with acute respiratory distress, requiring referral
to the ICU in Cayenne. Haemodynamic instability with septic
shock, renal insufficiency or hepatic insufficiency occurred in
three, one and one patients, respectively. Five patients had
an ICU SAPS II score that was >30 and a predicted mortality
that was >12%; this was especially apparent in the patient
that died (predicted mortality, 43.8%).
FIG. 1. Map of French Guiana indicating for each patient the place and the biotope of their residence and the place of contamination. The num-
ber indicates the case’s number (1 = case no. 1), the colour of the circle indicates the type of biotope (green = primary forest, red = semi-natu-
ral forest, yellow = littoral biotope) and the hatched colour indicates the place of contamination when it is different from the place of living. The
map of French Guiana is available on http://www.carnetderoutes.net/html/guyane/guyane.html. (Please note that it is the responsibility of the
author(s) to ensure that all URLs given in this article are correct and useable.)
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Pulmonary aspects of toxoplasmosis
For all patients, lung involvement started progressively with a
dry cough and chest pain during the first 2 weeks of disease
(Table 3, Photos 1 and 2). Clinical examinations revealed uni-
lateral or bilateral crackles, unilateral bronchial breathing or
areas of dullness. It quickly developed into respiratory insuffi-
ciency with acute dyspnoea, and significant abnormality in the
blood gas values. Nine patients presented a PSI score that cor-
responded to risk class IV or above; thus, patients had
between a 9.3% and 27% risk of death within 30 days. Accord-
ing to the North American–European Consensus Committee
(NAECC) [15], patients 1 and 6 suffered from acute lung injury
(ALI), whereas the other patients had acute respiratory dis-
tress syndrome (ARDS) on admission to the ICU.
Biological aspects
All patients tested negative for HIV and HTLV1-2 infection
and, except for patients 8 and 11, tests for other
infectious diseases remained negative. There were no
other particular abnormalities on admission, except for
mild inflammatory syndrome (median protein C reactive
value, 67 mg/L; range, 19.4–323), hyponatraemia (median
value, 130 mmol/L; range, 118–139) and elevated LDH
(median value, 1432 UI/L; range, 304–1720). Hepatic
enzyme activities were also elevated, with a stronger
increase in aspartate aminotransferase (median value, 3.9-
fold; range, 3–46.11) than in alanine aminotransferase
(median value, 2.8-fold; range, 1.18–11.5). Some biological
variables worsened after admission to the ICU, such as
anaemia (median hemoglobin value, 13.3 g/dL vs. 11.5 g/dL,
p 0.006) and the serum prothrombin time (median value,
83.5% vs. 61.5%, p 0.014). BAL analysis in seven patients
revealed inflammation with a median leucocyte value of
200/mm3, a predominance of lymphocytes (median value,
72%), and the presence of macrophages. No parasites
were detected on direct examination.
Immunological, molecular diagnosis and genotype analysis
of Toxoplasma
All patients presented serological evidence of recent Toxo-
plasma infection (Table 4). Although patient 4 displayed sero-
conversion with the appearance of Toxoplasma-specific IgM
and IgG in a second sample, the other patients presented sig-
nificant changes to Toxoplasma-specific IgG and IgM values
over a short period of time. Humoral response was character-
ized by high IgM index values in all patients and hypergamma-
globulinaemia in five patients (not shown). Molecular diagnosis
confirmed T. gondii infection in eight patients (Table 4). The
muscle biopsy (case 5) was positive even though the patient
had been receiving treatment for 22 days. Genotype analysis
of Toxoplasma DNA samples from eight patients revealed
atypical (unusual alleles at loci, shuffled combination of classi-
cal and/or unusual alleles) and unique multilocus genotypes.
Treatment and outcome
All patients received antibiotics immediately, which included
beta-lactams, fluoroquinolones, macrolides, and more or less
aminoglycosides due to the severity of symptoms (Table 4).
All patients received oral sulfadiazine and pyrimethamine for
a mean period of 42.4 days, except patient 11 who died on
day 6 after the start of this treatment. This patient had been
treated for longer than a month after the onset of symptoms,
unlike the other patients, who received treatment for only
2–3 weeks following the onset of symptoms. All patients
except patient 11, who died with a multiple organ dysfunc-
tion syndrome, recovered after the initiation of sulfadiazine
and pyrimethamine therapy. Side-effects due to sulfadiazine
were reported in two patients (cases 4 and 7), requiring
replacement with clindamycin. Three patients whilst under
treatment developed signs consistent with toxoplasmosis
infection: (i) cerebral oedema without focal lesions on day 5
of sulfadiazine/pyrimethamine treatment (patient 4), (ii)
intense polymyositis on day 16 of treatment requiring oral
corticoids (patient 5), and (iii) unusual hyperprolactinaemia
and galactorrhea with no other hormonal or cerebral abnor-
malities (patient 9). The appearance of long-lasting apyrexia
was delayed due to nosocomial infections (patients 1 and 4)
and complications such as phlebitis and pulmonary emboly
(patient 1). In addition to sulfadiazine/pyrimethamine treat-
ment, patients received ICU treatment based on the type of
organ dysfunction. Four patients required a high-concentra-
tion oxygen mask, and mechanical ventilation was required
by seven patients, four of whom received tracheal intubation.
Patients received these non-specific treatments over short
periods, lasting no more than 4 days, except for patient 4,
who required 16 days of mechanical ventilation (tracheal
intubation and non-invasive ventilation). Long-term follow-up
was possible in eight patients. Patient 2 presented three typi-
cal, active unilateral retinochoroiditis foci 6 years after the
acute infection; HIV and HTLV1-2 remained negative. No
complications were identified among the other patients.
Discussion
Since 1998, 65 cases of AT have been reported [5, 6, M.
Demar, personal communication] in French Guiana. They
involve wild T. gondii strains that circulate in this Amazonian
area between wild felids (definitive hosts), their prey (inter-
mediate hosts) and humans (accidental hosts) [5]. These
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strains exhibit an atypical and unique multilocus genotype
and present an unusual virulence in mice upon primary isola-
tion [6–10]. At the same time, little was known about the
genotypes of strains causing chronic and asymptomatic toxo-
plasmosis as they have silent expression in immunocompe-
tent adults. The seroprevalence of uncomplicated
toxoplasmosis was estimated at 72% among 179 adults hos-
pitalized for reasons other than acute toxoplasmosis from
1999 to 2001 [6]. A recent genetic study, including large
numbers of T. gondii isolates from domestic and wild animals
and from patients suffering with AT, genetically individualized
the ‘anthropized’ and the ‘wild’ T. gondii environmental popu-
lation with respectively low and high genetic diversity [16].
Genotypes from both environments cannot be classified into
the three main lineages described in North America or Eur-
ope.
AT presented as a significant infectious syndrome with
enlargement of the liver, the spleen and/or the lymph nodes.
Even though other organs can be affected such as the heart,
central nervous system (CNS) or eyes, the prognosis is
linked to lung involvement, which has been consistently
reported with variable levels of severity [5,6]. Our series of
11 French Guianese patients with disseminated toxoplasmo-
sis underscores the central role of life-threatening pneumo-
nia. Molecular typing of isolates confirmed their unique and
divergent genotypes. Clinical history was consistent with an
acute increase in pulmonary signals up to respiratory distress
syndrome associated with severe sepsis-like infection. Heart,
eye and/or muscle impairment emphasized this severity that
has only previously been reported in immunocompromised
patients [17–19]. Moreover, patients should be monitored
regularly for the rest of their lives, due to the possible
reactivation in immunodeficient and non-immunodeficient
patients. Despite recent findings in mouse experimental
models [20], pulmonary involvement during Toxoplasma infec-
tion is rare in immunocompetent subjects. It is mainly
observed in immunocompromised patients [12,17–19,21–23].
Pomeroy and Filice [22] reviewed 46 cases of Toxoplasma
pneumonia, of which 15 were among non-immunodeficient
patients. This has been followed by recent sporadic reports
[6,24–27].
Neither pulmonary symptoms nor specific findings on
chest radiography were found to distinguish Toxoplasma
pneumonia from pneumonia due to more common patho-
gens. A high level of LDH can be an adjunctive marker, as
previously discussed [28]. Diagnosis was usually established
by visualizing tachyzoites in lung tissue or fluids; however,
the sensitivity of the method is inconsistent [29,30] and may
be dependent on the amount of T. gondii in specimens. PCR
analysis is increasingly regarded as the most sensitive method
for the diagnosis of Toxoplasma pneumonia [12]; this was
similarly observed in our series. In addition, blood seemed
to be most suitable for detecting T. gondii, even 30 days after
infection onset (cases 8, 11). The T. gondii infection had
spread to the lungs, inducing necrotizing pneumonitis [31],
mostly as part of toxoplasmosis dissemination to multiple
organs via parasitaemia, which can lead to septic shock. Wild
Amazonian strains appear to be more aggressive with specific
pulmonary tropism. This particular clinical feature may also
be the result of an overstimulation of immune response, the
human immune system being unsuited to such strains. So far,
no particular predisposing factors for T. gondii lung involve-
ment have been described elsewhere.
Several hypotheses, other than those relating to virulent
strains, can be suggested to explain this severity. (i) A delay
in introducing disease management (i.e. patient 11, who died,
PHOTO 1. Thoracic imaging of Case 4 at ICU admission (chest X-
Ray).
PHOTO 2. Thoracic imaging of Case 2 at ICU admission (chest
computed tomography).
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did not received adequate care early enough). Indeed,
patients that survived, despite increased severity (SAPS II,
PSI), were managed within 2–3 weeks after the onset of
symptoms (patients 3, 4, 5 and 7). (ii) Toxoplasma gondii para-
sitic stage (i.e. ingestion of oocysts). All patients displayed
several risk factors for toxoplasmosis exposure. Unfortu-
nately, none of these risk factors allowed the identification
of the infective stage, except in patient 2, who was vegetar-
ian. (iii) Host susceptibility; however, except for patient 1
who had sickle cell disease, well-known to promote compli-
cations in infection, no other patients had predisposing fac-
tors and almost all ethnic groups were represented. The
inoculum effect may also be mentioned. One of the most
severely ill patients (patient 4) consumed pieces of raw game
meat (carpaccio), which could contain a significant amount of
living parasites. However, this couldn’t be proved as no path-
ological or molecular studies have been carried out on meat.
Further in vivo investigation is essential to understand the
basic mechanism of virulence of these novel isolates.
Conclusion
Although AT remains prevalent in French Guiana, the num-
ber of new life-threatening cases has decreased since 2004
(nine patients reported from 2002 to 2004 vs. two patients
from 2005 to 2010; M. Demar, unpublished data), probably
due to the population and physician awareness. AT is well
known in French Guiana and physicians should be aware of
such severe cases of acquired toxoplasmosis, which should
be suspected in any lung infections with a long lasting high
fever in patients who live in or have recently visited the
Amazonian region or more generally the neotropical rain
forest.
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